Claims for Patent: 5,849,484

Summary for Patent: 5,849,484

Title:	In vitro assay for inhibitors of the intron self-splicing reaction in Pneumocystis carinii
Abstract:	The present invention pertains to an in vitro method for assaying for an inhibitor of the catalytic Group I self-splicing intron reaction in the nuclear rRNA genes of Pheumocystis carinii which comprises the steps of (a) providing a DNA template containing the intron (I) from the 26S rRNA gene in Pneumocystis carinii and a portion of the 5\' and 3\' flanking exons (E1 and E2, respectively) between nucleotides 1963 and 2267 of 26S rRNA (660 nucleotides of amplified rRNA gene including the group I intron); (b) preparing an RNA precursor by transcription of the DNA template in the presence of labeled nucleoside triphosphates to produce a labeled RNA precursor (E1-I-E2); (c) purifying the RNA precursor; (d) incubating the RNA precursor and the inhibitor in the presence of guanosine triphosphate and magnesium ions; and (e) determining the degree of inhibition by the inhibitor on the intron splicing reaction in the RNA precursor by measuring the amount of labeled splicing intermediates and splicing products.
Inventor(s):	Leibowitz; Michael J. (Manalpan, NJ), Liu; Yong (Piscataway, NJ)
Assignee:	University of Medicine & Dentistry of NJ (Piscataway, NJ)
Application Number:	08/491,690
Patent Claims:	1. An in vitro method for assaying for an inhibitor of the catalytic Group I self-splicing intron reaction in the nuclear rRNA genes of Pneumocystis carinii which comprises the steps of: (a) providing a DNA template containing the intron (I) from the 26S rRNA gene in Pneumocystis carinii and a portion of the 5' and 3' flanking exons, E1 and E2, respectively, between nucleotides 1963 and 2267 of 26S rRNA, 660 nucleotides of amplified rRNA gene including the group I intron; (b) preparing an RNA precursor by transcription of the DNA template in the presence of labeled nucleoside triphosphates to produce a labeled RNA precursor; (c) purifying the RNA precursor; (d) incubating the RNA precursor and the inhibitor in the presence of guanosine triphosphate and magnesium ions; and (e) determining the degree of inhibition by the inhibitor on the intron splicing reaction in the RNA precursor by measuring the amount of labeled splicing intermediates and splicing products. 2. The method according to claim 1, wherein the DNA template in step (a) is prepared by polymerase chain reaction amplification of the intron from the 26S rRNA gene and the portion of the 5' and 3' flanking exons between nucleotides 1963 and 2267 of 26S rRNA, wherein the amplification results in synthesis of a product of 660 nucleotides of amplified rRNA gene. 3. The method according to claim 1, wherein the DNA template in step (a) is prepared by polymerase chain reaction amplification of a precursor-RNA-derived cDNA with two oligodeoxyribonucleotide primers, wherein one primer is collinear with the 5' terminus of the RNA precursor and has a 17-nucleotide extension on its terminus consisting of the positive strand of a consensus bacteriophage SP6 promoter and the other primer is collinear with the inverse complement of the 3' terminus of the RNA precursor. 4. The method according to claim 3, wherein the two oligodeoxyribonucleotide primers are 4208 (5'-ATTTAGGTGACACTATAGAAGCTATTGGACCAGACGGGAAC-3') (SEQ ID NO:33), in which the first 17 nucleotides are a bacteriophage SP6 promoter, and 4358 (5'-GACGAGGCATTTGGCTACC-3') (SEQ ID NO:34) to amplify the region between nucleotides 1963 and 2267 of 26S rRNA. 5. The method according to claim 4, wherein the two oligodeoxyribonucleotide primers are 4208 (5'-ATTTAGGTGACACTATAGAAGCTATTGGACCAGACGGGAAC-3') (SEQ ID NO:33) and 3734 (5'-GGGTGAACAATCCAACGCTTACCG-3') (SEQ ID NO:35) to amplify the region between nucleotides 1963 and 2903 of 26S rRNA. 6. The method according to claim 1, wherein the DNA template in step (a) is a recombinant DNA plasmid linearized by cleavage with a suitable restriction enzyme. 7. The method according to claim 1, wherein the RNA precursor in step (b) is prepared by transcription of the DNA template by SP6 RNA polymerase. 8. The method according to claim 1, wherein the labeled nucleoside triphosphate, in step (b) are [.alpha.-.sup.32 P]guanosine triphosphate or [.alpha.-.sup.32 P]uridine triphosphate. 9. The method according to claim 1, wherein the RNA precursor in step (c) is purified by polyacrylamide gel electrophoresis. 10. An in vitro method for assaying for an inhibitor of the catalytic Group I self-splicing intron reaction in the nuclear rRNA genes of Pneumocystis carinii which comprises the steps of: (a) providing a DNA template containing the intron (I) from the 26S rRNA gene in Pneumocystis carinii and a portion of the 5' and 3' flanking exons, E1 and E2, respectively between nucleotides 1963 and 2267 of 26S rRNA, 660 nucleotides of amplified rRNA gene including the group I intron; (b) preparing an RNA precursor by transcription of the DNA template to produce a RNA precursor; (c) purifying the RNA precursor; (d) incubating the RNA precursor and the inhibitor in the presence of labeled guanosine triphosphate and magnesium ions; and (e) determining the degree of inhibition by the inhibitor on the intron splicing reaction in the RNA precursor by measuring the amount of labeled splicing intermediates and splicing products. 11. The method according to claim 10, wherein the DNA template in step (a) is prepared by polymerase chain reaction amplification of the intron from the 26S rRNA gene and the portion of the 5' and 3' flanking exons between nucleotides 1963 and 2267 of 26S rRNA, wherein the amplification results in synthesis of a product of 660 nucleotides of amplified rRNA gene. 12. The method according to claim 11, wherein the DNA template in step (a) is prepared by polymerase chain reaction amplification of a precursor-RNA-derived cDNA with two oligodeoxyribonucleotide primers, wherein one primer is collinear with the 5' terminus of the RNA precursor and has a 17-nucleotide extension on its terminus consisting of the positive strand of a consensus bacteriophage SP6 promoter and the other primer is collinear with the inverse complement of the 3' terminus of the RNA precursor. 13. The method according to claim 14, wherein the two oligodeoxyribonucleotide primers are 4208 (5'-ATTTAGGTGACACTATAGAAGCTATTGGACCAGACGGGAAC-3') (SEQ ID NO:33), in which the first 17 nucleotides are a bacteriophage SP6 promoter, and 4358 (5'-GACGAGGCATTTGGCTACC-3') (SEQ ID NO:34) to amplify the region between nucleotides 1963 and 2267 of 26S rRNA. 14. The method according to claim 14, wherein the two oligodeoxyribonucleotide primers are 4208 (5'-ATTTAGGTGACACTATAGAAGCTATTGGACCAGACGGGAAC-3') (SEQ ID NO:33) and 3734 (5'-GGGTGAACAATCCAACGCTTACCG-3') (SEQ ID NO:35) to amplify the region between nucleotides 1963 and 2903 of 26S rRNA. 15. The method according to claim 10, wherein the DNA template in step (a) is a recombinant DNA plasmid linearized by cleavage with a suitable restriction enzyme. 16. The method according to claim 10, wherein the RNA precursor in step (b) is prepared by transcription of the DNA template by SP6 RNA polymerase. 17. The method according to claim 10, wherein the RNA precursor in step (c) is purified by polyacrylamide gel electrophoresis. 18. The method according to claim 10, wherein the labeled guanosine triphosphate in step (d) is [.alpha.-.sup.32 P]guanosine triphosphate.

Details for Patent 5,849,484

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26